Loading organizations...
Nucleate is a non-profit, student-led organization empowering the next generation of biotechnology leaders. It offers the Activator program, a six-month, equity-free cohort for academic biotech founders. This program provides education, mentorship, and resources, enabling participants to translate scientific discoveries into viable ventures and accelerate impactful solutions.
The organization originated from scientific trainees identifying a gap between academic innovation and market impact. Early contributors like Marissa Pettit Jones, Oliver Dodd, and founding President Soufiane, as student leaders, built a structured support system. Their insight cultivated a global community guiding aspiring bio-entrepreneurs in research commercialization.
Nucleate primarily serves scientific trainees and academic founders globally, equipping them with tools and networks for venture creation. Its vision fosters a more inclusive, interconnected biotech ecosystem, building bridges across life sciences, and increasing entrepreneurial access. It cultivates innovators addressing critical biomedical and ecological challenges.
Key people at Nucleate.
Nucleate was founded in 2019 by Jun Jeon (Co-Managing Director and Co-founder of Philadelphia Chapter) and Kevin Dong (Co-Founder and Co-Managing Director of the Genesis Program).
Key people at Nucleate.
Nucleate was founded in 2019 by Jun Jeon (Co-Managing Director and Co-founder of Philadelphia Chapter) and Kevin Dong (Co-Founder and Co-Managing Director of the Genesis Program).
Nucleate is a student-led nonprofit organization that represents the largest global community of bio-innovators, empowering academic trainees to launch biotech ventures.[1] Its mission focuses on identifying future bio-entrepreneurs, educating scientists and business students, building bridges in the biotech ecosystem, accelerating impactful academic bioventures, and increasing access for underrepresented groups.[1] Through its flagship equity-free Activator program—a six-month cohort for academic founders—Nucleate has supported over 600 teams that raised more than $570 million USD and created over 800 jobs in seven years.[1][4] With world-class advisors like George Church and Reshma Shetty, and chapters worldwide, Nucleate drives high-potential life sciences research into ventures addressing biomedical and ecological challenges.[1]
Nucleate emerged from Harvard's ecosystem to bridge talent pools like PhDs, post-docs, MBAs, and medical students, fostering biotech entrepreneurship.[3] Founded around 2018 (with incorporation following early meetings encouraged by figures in translational medicine), it started as a response to the need for structured support in turning academic science into businesses—one alumni story notes pitching VCs post-Nucleate involvement, securing initial funding from 2048 Ventures.[2] Key evolution includes expanding the Activator program globally, from regional chapters to a unified network, with rigorous curricula on team formation, workshops, and pitch showcases.[1][3] By 2024-2025, it released its first impact report, highlighting growth from origins to serving 100+ ventures raising $190M initially, now scaled significantly.[1][4]
Nucleate rides the academic-to-biotech translation wave, capitalizing on surging demand for deep-tech life sciences amid AI-drug discovery, climate biotech, and post-pandemic innovation.[1][4] Timing aligns with ecosystem gaps—high-potential research often stalls without business training—enabling Nucleate to boost venture volume and quality for human/planetary health challenges.[1] Market forces like VC interest in academic spinouts (evidenced by alumni funding) and global talent shortages favor its model, while it influences the ecosystem by diversifying access, sparking communities, and creating job pipelines.[1][2][4]
Nucleate's trajectory points to expanded global scale, with more chapters, refined Eco track for sustainability biotech, and deeper alumni integration for follow-on support amid rising deep-tech funding.[4] Trends like AI-biotech convergence and climate imperatives will amplify its role, potentially doubling impact metrics as it evolves influence from talent feeder to ecosystem architect. This positions Nucleate as the go-to launchpad for bio-innovators, sustaining its lead in empowering the next wave of biotech leaders.[1][4]
